Net Present Value Model: F. Hoffmann-La Roche Ltd’s Tominersen
Powered by
Gain invaluable insights that can revolutionize your business
Overview
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
F. Hoffmann-La Roche Ltd’s Tominersen Drug Details:
Tominersen (RG-6042) is under development for the treatment of Huntington’s disease. The drug candidate is administered through intrathecal route. It is a chimeric 2′-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA. It is based on antisense technology and brain shuttle technology. It is a new molecular entity (NME) and acts by targeting HTT.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Reasons to Buy
– Better understand the quantitative value of a specific drug
– Obtain another data source to use in the valuation of the company/drug
– Create or support internal NPV models to improve accuracy
– Understand a drug’s expected profit, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Pharmaceuticals reports

